ArticleCurrent medicinal chemistry2026
An Advanced Network Pharmacology Study Reveals the Multi-Pathway and Multi-Gene Regulatory Mechanism of Jinbai Heat-clearing Prescription in HPV-induced Cervical Cancer via Molecular Docking and Microarray Data Analysis.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCervical cancer, primarily driven by high-risk human papillomavirus (HPV) infection, remains a global health challenge due to limited therapeutic efficacy and adverse effects of conventional treatments. Jinbai Heat-Clearing Prescription (JBHCP), a Traditional Chinese Medicine (TCM), exhibits potential against HPV-associated cervical cancer, yet its molecular mechanisms are unclear. This study aimed to elucidate JBHCP's multitarget regulatory mechanisms in HPV-induced cervical carcinogenesis.
methodsNetwork pharmacology, UHPLC-Q-TOF-MS-based metabolomics, and microarray data analysis were integrated to identify the bioactive components and therapeutic targets of JBHCP. Molecular docking and 60 ns Molecular Dynamics (MD) simulations were used to assess the interactions between key compounds (JBHCP673, JBHCP727) and cyclin-dependent kinases (CDK1/ CDK2). Gene Ontology (GO), KEGG pathway enrichment, and Protein-Protein Interaction (PPI) network analyses were performed to explore biological functions and signaling pathways.
resultsUHPLC-Q-TOF-MS identified 816 compounds in JBHCP, with 86 meeting drug-likeness criteria. Network analysis revealed 215 shared targets between JBHCP and HPV-induced cervical cancer, including CDK1 and CDK2 as core regulators. Enrichment analysis highlighted JBHCP's involvement in cell cycle regulation, PI3K/AKT, and STAT3 signaling pathways. Molecular docking demonstrated strong binding affinities of JBHCP727 with CDK1 (-7.36 kcal/mol) and CDK2 (-6.13 kcal/mol). MD simulations confirmed stable binding of JBHCP727 to CDK1/2, while JBHCP673 exhibited instability. ADMET predictions supported JBHCP727's drug-like properties. DISCUSSION: JBHCP exerts anticancer effects by targeting CDK1/2, disrupting cell cycle progression, and modulating oncogenic pathways (PI3K/AKT, STAT3). The stability of JBHCP727-CDK complexes suggests its role in inhibiting HPV-driven proliferation. Multi-component synergy enables JBHCP to act on diverse pathways, aligning with TCM's "multitarget" paradigm.
conclusionThis study provides the first systematic evidence of JBHCP's multi-pathway mechanism against HPV-associated cervical cancer, emphasizing CDK1/2 inhibition as a key therapeutic strategy. JBHCP727 emerges as a promising lead compound. Further in vivo and clinical validation is warranted to translate these findings into clinical applications.
Indexed as
Identifiers
40798963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.